invasive infections like meningitis and osteomyelitis in immune compromised patients and children. 4 Salmonella typhi is mostly acquired directly or indirectly through human feces by fecal-oral route from the diseased person or a carrier. Threat of growing resistance to antibiotics is of grave concern to human health. Resistant strains also lead to prolonged illness and more rate of complications. 5 Resistance of Salmonella Typhi to chloramphenicol, cotrimoxazole and ampicillin developed in the 1980s. This led to an increasing use of fluoroquinolones. Gradually resistance also developed to fluoroquinolones. High prevalence of antibiotic resistant Salmonellae leads to treatment failure. Multi-drug resistant (MDR) strains (resistant to chloramphenicol, ampicillin and cotrimoxazole) are very common. Resistance to third generation cephalosporins is beginning to emerge. Due to development of resistance, therapeutic options for treatment of typhoid and other Salmonella infections are getting limited. Outbreaks of MDR Salmonella (S.) Typhi may be difficult to manage, especially in developing countries where resources are already limited. Outbreaks have been reported throughout the world especially in south-east Asia, Indian subcontinent, Africa and South America. 6, 7 An outbreak of MDR S. Typhi in late 1990s in Tajikistan caused more than 24,000 infections. 8 Hence, there is dire need to explore new avenues for treatment of resistant Salmonellae. The aim of this study was to determine MIC of Imipenem against Salmonella typhi which is not commonly used for treatment of Salmonella infections.
Materials and method:
The interventional study was performed in the department of pharmacology and therapeutics in collaboration with the department of Microbiology at Ad-din Sakina Women's Medical College, Jashore during the period of January 2018 to May 2018.
Basic Research

Determination of Minimum Inhibitory Concentration (MIC) of Imipenem against Salmonella typhi
Collection of antibiotic Imipenem: A Betalactum antibiotic (Injectable form), 500 mg vial was bought from local market, manufactured by Renata Pharmaceuticals LTD, Bangladesh.
Test organism: Standard reference strain of Salmonella typhi, ATCC 24683 was collected from Department of Microbiology, Ad-din Sakina Women's Medical College, Jashore.
Procedure of Experiment: Determination of MIC of Imipenem against test organisms
Technique: Broth dilution.
Preparation of stock solution of Imipenem:
Five hundred (500) mg of Imipenem powder was mixed well with 500 ml of sterile Distilled Water (DW) by sterile syringe. The prepared Imipenem injection had the concentration of 500 mg in 500 ml. So, 1 ml solution contain 1 mg Imipenem (Stock Imipenem solution-I). Then 1 ml of stock Imipenem solution-I was mixed with 99 ml of sterile D/W. This 1:100 dilution of stock Imipenem solution-I had the concentration of 10 µg/ml. This solution was marked as Stock Imipenem Solution-II which was used as stock solution for the determination of MIC of Imipenem.
Calculations:
Imipenem 500 mg + 500 ml D/W. So, 500 mg Imipenem in 500 ml This stock Imipenem solution-II (concentration 10 µg/ml) was used for the determination MIC of Imipenem by broth dilution technique.
Preparation of different concentrations of Imipenem solution:
Set -I: Imipenem solution was made by adding 0.25 ml of stock Imipenem solution-II with 9.75 ml of Trypticase soya broth medium. The concentration of Imipenem in this dilution was 0.25 µg/ml. Similarly, Set-III, IV, V and VI of Imipenem solution respectively were made by adding measured amount of stock Imipenem solution-II with measured amount of broth medium. The concentrations of Imipenem were 0.75 µg/ml, 1 µg/ml, 1.5 µg/ml and 2 µg/ml respectively: (Table 1) .
Control -1:
was made with 10 m1 of Trypticase soya broth medium (to be inoculated with bacterial suspension) in test tubes.
Control -2:
was made with 10 m1 of Trypticase soya broth medium (no inoculation with bacterial suspension) in test tubes. (Table 1) With each 10 ml preparation except control-1 (set VII) 20 µl bacterial suspensions were added after matching its opacity with that of 0.5 McFarland Standard. 
Inoculation of bacterial suspension to different concentrations of stock Imipenem in test tubes:
After matching the turbidity of bacterial suspension with 0.5 McFarland standard, 20 µl or one drop (0.02 m1) of bacterial suspension of Salmonella typhi is inoculated. These inoculums were also added to the control -2 except Control-1.
Incubation:
The test tubes were marked set wise with black marker and were placed in the incubator at 37° C for 18 -24 hours.
Examinations of test organisms in different dilutions and concentrations of Imipenem:
After 18 to 24 hours of incubation at 37° C, the growth of test organisms in each preparation of Imipenem was examined and compared against that of control by matching their turbidity.
The clear preparations were considered as no growth of bacteria and turbid one as growth of bacteria. The MIC was reported as lowest concentration of Imipenem required to prevent the visible growth of test organisms. The observations and results of the experiment were shown in table-2.
Subculture of materials from effective dilutions of Imipenem in MacConkey agar media:
The materials from last two sets of growth and all sets of no growth of Imipenem preparations were sub cultured in the pure MacConkey (solid) media plates (without antibiotic and antibiotic mixed media). After 18 to 24 hours of incubation at 37°C, the growth of test organisms were examined.
Observations and results:
Table-2 shows visible growth of Salmonella typhi observed at Set-I to Set-II. But the organisms failed to grow at Set-III to Set-VI. So the minimum inhibitory concentration (MIC) of Imipenem against Salmonella typhi was in 0.75µg/ml. Table-2 also showed control-1 containing Trypticase soya broth medium without any bacterial inoculam had no visible growth and control -2 containing Trypticase soya broth medium with bacterial inoculam observed their visible growth.
Result of Experiment:
The MIC of Imipenem against Salmonella typhi was 0.75 µg/ml at set III. 
